Home - Pharmaceutical Markets

Friday, July 30, 2010 > Home

Industry Sectors

US experts back AstraZeneca blood thinner

US advisers backed a potential blockbuster blood thinner from AstraZeneca on Wednesday, a victory for a company seeking new drugs to offset expiring patents on some of its best-selling medicines, Reuters reports. [FULL STORY]
Illumina acquires Helixis for $105M

Illumina has unveiled a deal to buy Helixis for up to $105 million, fiercebiotech.com reports. [FULL STORY]
Allergan eye drug wins EU approval

Allergan on Wednesday said that its drug Ozurdex has become the first drug in Europe approved to treat an eyesight-endangering condition in which fluid builds up in the retina because of a clogged vein, Reuters reports. [FULL STORY]
Sanofi-Aventis investors win revival of Zumulti lawsuit

A US judge has reinstated a lawsuit accusing Sanofi-Aventis of misleading investors about the likelihood of US regulatory approval of its weight-loss pill Zimulti, Bloomberg reports. [FULL STORY]
Court ruling could pave way for generics of Eli Lilly's Gemzar

A decision by a US appeals court could pave the way for cheaper generic forms of Eli Lilly's Gemzar cancer drug to be launched in the US beginning in mid-November, Reuters reports. [FULL STORY]